B+
Bull case
30%
Probability
Target price
$24.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
OSCR
Oscar HealthDNYSE / Insurance
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+26.0
Positive
Company
-
Unavailable
Macro
+26.0
Positive
Pulse
-
Unavailable
Weekly research (10D)
-32.0
Negative
Sentiment proxy
+16.0
Score
AI commentary
Headline tone improved materially after the May 6, 2026 earnings release because results were strong and guidance was reaffirmed. The May 7, 2026 anchor close of $20.87 indicates the market kept a positive post-print reaction, and recent coverage framed the move around the earnings beat and margin improvement. Even so, this remains a medium-conviction setup because the checked packet does not contain a robust verified analyst-revision set, social coverage is not available, and the stock is already above the packet's stale median target summary.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystQ1 beat and reaffirmed 2026 outlook reset the near-term tape, but durability still needs post-print digestionMedium impact
Oscar reported Q1 2026 total revenue of $4.65 billion, MLR of 70.5%, earnings from operations of $704.1 million, diluted EPS of $2.07, and reaffirmed full-year 2026 guidance on May 6, 2026. Management attributed the margin step-up to higher membership, rate increases, favorable prior-period reserve development, and fixed-cost leverage, which is strong evidence of near-term execution but also means investors still need to test how much of the beat was seasonal versus durable [#8-K-2026-05-06] [#10-Q-2026-05-07].
2026-09-30catalystLucie adds a new growth narrative, but adoption proof is still missingMedium impact
Oscar launched Lucie Health Marketplace in April as a broader consumer shopping and distribution layer, which could support cross-sell and channel expansion, but the checked evidence still lacks disclosed adoption, conversion, or monetization metrics. That keeps Lucie as an option-value catalyst rather than a thesis anchor for now.
2026-12-31catalystThe 2026 profitability recovery thesis remains the main valuation driverHigh impact
The core medium-term question is whether Oscar can convert rapid membership growth into full-year profitability as 2026 progresses. The company reaffirmed its 2026 outlook after Q1, while the February setup had already framed the year around materially better revenue, MLR, SG&A, and operating profit than 2025. If medical cost discipline and risk-adjustment assumptions hold through the higher-cost back half, the recovery case can extend; if they slip, the stock has less room for error after the post-earnings rally [#8-K-2026-05-06] [#10-K-2026-02-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology